

**RECEIVED
CENTRAL FAX CENTER
DEC 21 2004**

PTO/SB/82 (08-04)

Approved for use through 11/30/2008 OMB 0851-0039
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**REVOCATION OF POWER OF
ATTORNEY WITH
NEW POWER OF ATTORNEY
AND
CHANGE OF CORRESPONDENCE ADDRESS**

Application Number	09/896,791
Filing Date	June 28, 2001
First Named Inventor	Berkenstern
Art Unit	1842
Examiner Name	Nickol, Gary B
Attorney Docket Number	76272

I hereby revoke all previous powers of attorney given in the above-identified application.

A Power of Attorney is submitted herewith

OR

I hereby appoint the practitioners associated with the Customer Number: 28288

Please change the correspondence address for the above-identified application to:

The address associated with
Customer Number:

28288

OR

<input type="checkbox"/> Firm or Individual Name	
---	--

Address	
---------	--

City		State		Zip
------	--	-------	--	-----

Country	
---------	--


Telephone		Fax	
-----------	--	-----	--

I am the:

Applicant/Inventor

Assignee of record of the entire interest. See 37 CFR 3.71
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/86)

SIGNATURE of Applicant or Assignee of Record

Signature	
-----------	---

Name	Mattias Kalén
------	---------------

Date	13 December 2004
------	------------------

Telephone	+46 708 71 70 00
-----------	------------------

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

Total of 1 forms are submitted

This collection of information is required by 37 CFR 1.35. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-8189 and select option 2.

PTO/SB/08 (08-04)

Approved for use through 07/31/2005 OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Berkenstam et al.Application No./Patent No.: 09/888,791 Filed/Issue Date: June 29, 2001

Entitled:

ANGIOGENETICS SWEDEN AB a Corporation
 (Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

- 1 the assignee of the entire right, title, and interest; or
 2 an assignee of less than the entire right, title and interest
 The extent (by percentage) of its ownership interest is _____ %

In the patent application/patent identified above by virtue of either:

A An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

B A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

- 1 From: Inventors To: Biovitrum AB
 The document was recorded in the United States Patent and Trademark Office at
 Reel 012869, Frame 0346, or for which a copy thereof is attached
- 2 From: Biovitrum AB To: Angiogenetics Sweden AB
 The document was recorded in the United States Patent and Trademark Office at
 Reel 013438, Frame 0274, or for which a copy thereof is attached
- 3 From: _____ To: _____
 The document was recorded in the United States Patent and Trademark Office at
 Reel _____, Frame _____, or for which a copy thereof is attached


Additional documents in the chain of title are listed on a supplemental sheet

Copies of assignments or other documents in the chain of title are attached

(NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08)

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee

13 December 2004



Signature

Date

Mattias Kalén+46 708 71 70 00

Printed or Typed Name

Telephone Number

Chief Executive Officer

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-8198 and select option 2